Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29945924 | 0.91 | TRPV3 (0.44) | SMN1; SMN2DPP4TRPV3MAPTTP53 | |
| SCHEMBL29945852 | 0.89 | GPR119 (0.53) | SMN1; SMN2GPR119DPP4TRPV3MAPT | |
| SCHEMBL29945937 | 0.87 | SMN1; SMN2 (0.38) | SMN1; SMN2GPR119DPP4MAPTTP53 | |
| SCHEMBL29945994 | 0.87 | GPR119 (0.46) | SMN1; SMN2GPR119TRPV3TP53LMNA | |
| SCHEMBL29946020 | 0.79 | MEN1 (0.48) | SMN1; SMN2GPR119TP53LMNATHRB | |
| SCHEMBL29946017 | 0.79 | MEN1 (0.48) | SMN1; SMN2GPR119TP53LMNATHRB | |
| SCHEMBL24485767 | 0.79 | GLP1R (0.56) | SMN1; SMN2TRPV3 | |
| SCHEMBL29668702 | 0.79 | GLP1R (0.56) | SMN1; SMN2TRPV3 | |
| SCHEMBL13060199 | 0.78 | DPP4 (0.52) | SMN1; SMN2GPR119DPP4 | |
| SCHEMBL29946162 | 0.77 | HTR6 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022184849-A1 | GLP-1R AGONISTS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | LES LABORATOIRES SERVIER (FR) | 2022-09-09 | — | — | WO | disclosed |